Upadacitinib ranked first for UC induction in network meta-analysis

Interleukin-23 p19 inhibitors ranked most favorably for serious adverse events and discontinuations across 33 trials, though the authors rated confidence in the safety estimates as lower.

11/06/2026

• by Julie Greenbaum